The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD-1 Inhibitors

被引:0
|
作者
Li, Xingzhi [1 ,2 ]
Tang, Zhihong [1 ]
Pang, Qingqing [1 ]
Wang, Xiaobo [1 ]
Bai, Tao [1 ]
Chen, Jie [1 ]
Wei, Meng [1 ]
Wei, Tao [1 ]
Li, Lequn [1 ]
Wu, Feixiang [1 ,3 ]
机构
[1] Guangxi Med Univ, Canc Hosp, Dept Hepatobiliary Surg, Nanning 530021, Peoples R China
[2] Nanchong Cent Hosp, Clin Coll 2, North Sichuan Med Coll, Dept Hepatobiliary Surg, Nanchong, Peoples R China
[3] Guangxi Med Univ, Key Lab Early Prevent & Treatment Reg High Frequen, Minist Educ, Nanning, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; salvage surgery; early tumor progression; post-progression survival; real-world; CHEMOEMBOLIZATION; SURVIVAL;
D O I
10.2147/JHC.S481816
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis of initially unresectable hepatocellular carcinoma (iuHCC) has been improved by TACE with TKIs and PD-1 inhibitors (TTP). However, the role of timing of tumor progression and and early salvage surgery during TTP therapy remains unclear. Patients and Methods: The data of 151 patients who received TTP for iuHCC consecutively between November 2019 and December 2022 were retrospectively analyzed. The X-Tile software was used to determine the optimal threshold of progression timing to differentiate the post-progression survival (PPS) for patients with tumor progression, ultimately yielding 9 months as the optimal cut-off time. Early tumor progression was defined as patients with tumor recurrence (surgical patients) or progressive disease by mRECIST (nonsurgical patients) within 9 months of initial treatment. Accordingly, early salvage surgery was defined as salvage surgery performed within 9 months of the initial treatment. Results: Out of all the patients, 55 (36.4%) patients showed early tumor progression, 33 (34.4%) showed late tumor progression, and 63 (41.7%) showed non-progression. Patients who experienced early tumor progression had a median PPS of 5.2 months, while those with late tumor progression had a median PPS of 16.8 months (P < 0.001). Multivariable analysis revealed a robust independent correlation between early tumor progression and PPS (HR = 3.279, 95% CI: 1.591-6.756; P = 0.001). Patients who received early salvage surgery showed a considerably lower early tumor progression rate when compared with patients who did not receive early surgery (12.5% vs 42.9%, P = 0.002). The multivariable analysis revealed that early salvage surgery was an independent factor influencing early tumor progression (OR = 0.246; 95% CI: 0.078-0.773; P = 0.016). Conclusion: Early tumor progression is associated with worse PPS in patients with iuHCC receiving TTP therapy. Early salvage surgery can further improve patient outcomes by lowering the incidence of early progression.
引用
收藏
页码:1641 / 1652
页数:12
相关论文
共 50 条
  • [1] The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study
    Ding, Zongren
    Fang, Guoxu
    Tang, Yanyan
    Zeng, Yongyi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [2] Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
    Zhao, Shu
    Zhou, Minhang
    Wang, Peng
    Yang, Jing
    Zhang, Dong
    Yin, Fan
    Song, Peng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [3] Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
    Li, Xingzhi
    Chen, Jie
    Wang, Xiaobo
    Bai, Tao
    Lu, Shaolong
    Wei, Tao
    Tang, Zhihong
    Huang, Chengwen
    Zhang, Bin
    Liu, Bowen
    Li, Lequn
    Wu, Feixiang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
    Zhang, Ze
    Jiao, Tianyu
    Li, Junfeng
    Hu, Bingyang
    Zhang, Wenwen
    Wang, Zhijun
    Wan, Tao
    Wang, Yafei
    Lu, Shichun
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [5] Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
    Ze Zhang
    Tianyu Jiao
    Junfeng Li
    Bingyang Hu
    Wenwen Zhang
    Zhijun Wang
    Tao Wan
    Yafei Wang
    Shichun Lu
    World Journal of Surgical Oncology, 21
  • [6] Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma
    Pang, Beichuan
    Zuo, Bangyou
    Huang, Liang
    You, Xinyu
    Liu, Tao
    Hao, Jianjie
    Yuan, Chengxiang
    Yang, Chong
    Lau, Wan Yee
    Zhang, Yu
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137
  • [7] Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD-1 inhibitors? Further validation should be performed
    Yang, Shiye
    Liang, Huoqi
    Li, Xing
    Qian, Jiayi
    Ming, Zhibing
    HEPATOLOGY INTERNATIONAL, 2024, 18 (03) : 1058 - 1059
  • [8] Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
    Qu, Shuping
    Zhang, Xiaobing
    Wu, Yutian
    Meng, Yan
    Pan, Hongyu
    Fang, Qiang
    Hu, Lei
    Zhang, Jin
    Wang, Ruoyu
    Wei, Lixin
    Wu, Dong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Reply to: "Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD-1 inhibitors? Further validation should be performed"
    Zeng, Zhen-Xin
    Wu, Jia-Yi
    Zhuang, Shao-Wu
    Yan, Mao-Lin
    HEPATOLOGY INTERNATIONAL, 2024, 18 (05) : 1589 - 1590
  • [10] Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
    Li, Xiaowei
    Fu, Zhigang
    Chen, Xiaoxia
    Cao, Kunkun
    Zhong, Jiaming
    Liu, Li
    Ding, Ning
    Zhang, Xiaoli
    Zhai, Jian
    Qu, Zengqiang
    FRONTIERS IN ONCOLOGY, 2022, 12